Articles tagged with Metastasis
Researchers at Johns Hopkins Medicine discover that tumor cells can spread through lymphatic vessels by releasing signaling molecules, which attract and facilitate the growth of new blood vessels. The HIV drug maraviroc blocks these signals, preventing breast cancer metastasis when combined with a VEGF-blocking drug.
Researchers identify protein p66ShcA as a biomarker for predicting breast cancer outcomes and identifying poor-prognosis cancers. The discovery aids understanding of epithelial to mesenchymal transition, a process enabling tumor cells to metastasize.
Scientists have identified a novel gene that predicts both breast cancer relapse and response to chemotherapy, enabling doctors to classify patients for more effective treatment. The discovery could help reduce metastasis and increase the effectiveness of chemotherapy.
Cancer cells that break away from tumors can prefer soft environments for growth and proliferation, researchers at the University of Illinois found. The study suggests that this preference may explain why soft tissues are more vulnerable to cancer metastasis and recurrence.
Researchers at Cold Spring Harbor Laboratory have discovered a new function of the body's most important tumor-suppressing protein, p53. A previously unknown variant of p53 called p53-psi reduces cell adhesion and promotes metastatic potential by interacting with cyclophillin D and generating reactive oxygen species.
A Cincinnati Cancer Center study finds that SapC-DOPS, a combination of lysosomal protein saposin C and phospholipid DOPS, targets and kills cancer cells, including those from breast and lung cancers. The treatment showed promise in animal models, with some tumors completely cured within 24 hours.
Researchers at Université catholique de Louvain successfully identified a family of pharmaceutical compounds that prevent the formation of human tumor metastasis. The study found that mitochondria can promote cell migration leading to metastasis, which can be blocked by specific antioxidants.
Scientists discovered a regulatory network contributing to abnormal cell proliferation in diseases like cancers and psoriasis. MicroRNA miR-21 is degraded through PAPD5, which breaks the pathway's disruption in many cancers.
A new study suggests that cancer metastasis, the spread of tumors from one part of the body to another, may occur through pure chance. Researchers used statistical models to show that 'common' cancer cells circulating in the bloodstream could, on rare occasions, cause metastasis.
Scientists at Salk Institute identify gene DIXDC1 that stops cancer cells from spreading, opening new avenues for treating aggressive lung and other cancers. The discovery provides hope for patients with limited treatment options.
Researchers successfully silenced chemokine receptor 4 in SH-SY5Y cells, inhibiting neuroblastoma cell invasion. This approach may provide a new therapeutic strategy for blocking neuroblastoma metastasis.
Researchers at MD Anderson Cancer Center have discovered that circulating tumor cells (CTCs) rely on the HER3 receptor protein to metastasize to the omentum, a fatty tissue covering abdominal organs. High expression of HER3 is associated with shorter survival in ovarian cancer patients.
Researchers isolated breast cancer cells from patients' blood and expanded them in the lab, identifying new mutations and drug susceptibility. The study found a promising drug, Ganetspib, effective in killing tumor cells with specific genetic mutations.
Researchers at Rockefeller University have identified a protein called TARBP2 that triggers breast cancer's spread by blocking other proteins linked to neurodegeneration. This finding suggests new cancer therapies targeting this 'master regulator' could be effective.
A new study published in the Journal of the American College of Surgeons reports that surgical resection improves survival among metastatic melanoma patients with limited liver disease. The five-year survival rate for surgical patients was 30%, compared to 6.6% for nonsurgical patients.
The phase III RECOURSE trial found that TAS-102 improves overall and progression-free survival in patients with metastatic colorectal cancer refractory to standard therapies. The study showed a median overall survival of 7.1 months for TAS-102, compared to 5.3 months for placebo.
A study by Princeton University researchers found that the Metadherin gene, implicated in promoting breast cancer tumors, only stimulates growth when bound to its partner protein SND1. The research reveals that MTDH plays a role in both initial tumor growth and metastasis, but not normal cell growth or development.
Adding MM-398 to standard treatment for metastatic pancreatic cancer improves overall and progression-free survival, according to a phase III trial. The combination therapy showed significant benefits over standard treatment alone, but with higher gastrointestinal side effects.
Experts cite five historical misconceptions in brain metastases research, including assuming all histologies are equal and neglecting total tumor burden. A new article calls for 'fresh thinking' and critical analyses to advance treatment.
Brain cancer specialists argue that current science is guiding compromising care, emphasizing the need for individualized treatment approaches. They identify five misconceptions that lead to poorer care, including assuming all tumor cell types act similarly and neglecting important biological differences.
Researchers at Albert Einstein College of Medicine will study how breast cancer cells move and spread in the body. They aim to develop a test that predicts which breast cancer tumors will metastasize, based on the presence of a trio of cells called a tumor microenvironment of metastasis.
Researchers found that restricting food to nematode worms triggers a state of arrested development, allowing them to live twice as long as normal. The study hints at an easier way to achieve human longevity and has implications for cancer research.
A new protein variant called VEGF-Ax discovered by Cleveland Clinic researchers slows the development of new blood vessels necessary for tumors to expand and metastasize. This discovery could lead to new diagnostic tools and improved treatments to reduce cancer spread, according to Dr. Paul Fox.
A new molecular breast imaging protocol using a higher dose of Tc-99m filtered sulfur colloid has been shown to improve the detection of advanced breast cancer. Imaging performed the day prior to surgery was more sensitive than imaging on the day of surgery, detecting 76% versus 49% of cases with metastasized lymph nodes.
A new PSMA-based imaging agent, F-18 DCFBC PET/CT, has been developed to detect prostate cancer and monitor treatment response. The study shows the agent's effectiveness in detecting both castration-sensitive and castration-resistant forms of the disease.
A Cornell research team has developed a new microfluidic device to isolate and study the most aggressive cancer cells. The device separates these cells from less aggressive ones, enabling researchers to analyze molecular changes that contribute to metastasis.
Researchers developed a new test that assesses metastatic risk by identifying specific cell types in tumor microenvironments. The test was more accurate than existing methods in predicting distant tumor spread and showed promise in tailoring therapy for breast cancer patients.
Scientists identified a new protein, hnRNPM, that plays a key role in reprogramming breast cancer cells to spread. Removing this protein significantly reduces the ability of breast cancer cells to metastasize to other organs.
Researchers found that reducing the frequency of bisphosphonate treatment from monthly to every three months after one year was non-inferior to continuing monthly treatment in terms of efficacy. The study also showed a reduced risk of serious side effects, including kidney-related adverse events.
A behavior-altering enzyme commonly used in depression medications has been linked to prostate cancer growth. Suppressing this enzyme may reduce or eliminate prostate tumor growth and metastasis, offering a potential new treatment for men with metastatic prostate cancer.
Researchers have created an innovative 3D test system that allows them to simulate human body functions, enabling the development of more effective cancer treatments. The artificial lung model, no bigger than a sugar cube, can be used to analyze treatment resistance and metastasis formation, potentially leading to personalized medicine.
Researchers found that calorie restriction decreased microRNA production, which promotes the extracellular matrix and prevents cancer cells from spreading. The study aims to test whether calorie restriction can improve outcomes for women with breast cancer in a clinical trial.
A study found that using positron emission tomography combined with computed tomography before surgery did not improve outcomes for patients with colorectal cancer and limited liver spread. The study suggests that PET-CT scans may not be necessary to change surgical management in these cases.
Researchers at the University of York discovered that breast cancer cells use a process similar to brain development to metastasize. Blocking sodium channels inhibits migration and invasiveness, making them a potential therapeutic target.
Researchers developed an assay to analyze poly-G repeat mutations in human cancer samples, revealing evolutionary relationships among tumor sites. The study found that individual patients had varying levels of genetic differences between primary tumors and metastases, suggesting early or late metastatic spread.
Researchers pinpoint normal cell type that can give rise to invasive bladder cancers, explaining recurrence after therapy and potential therapeutic targets. Most bladder cancers arise from a corrupted lining with high probability of progression.
A study by TGen found that specific growth factor receptors, HGFR/MET and FN14, are elevated in metastatic tumors of non-small cell lung cancer (NSCLC). Suppression of these receptors reduces tumor cell invasion. These findings suggest new targets for therapy to prevent or halt the spread of this deadly cancer.
Researchers inhibit heat shock protein 90, shutting off proteases that help ovarian cancer cells escape and spread. In mouse studies, ganetespib treatment reduced metastases, indicating potential therapeutic target for ovarian cancer.
The Deutsche Forschungsgemeinschaft (DFG) is establishing five new Research Units to explore innovative research directions in various fields. The new groups will focus on composite structures, personnel decisions, and metastatic cancer progression, with the goal of improving our understanding of these complex topics.
Researchers at Washington State University have found that peach extracts can inhibit the growth of breast cancer cells and their ability to spread. The study suggests that these compounds could be a novel addition to therapies reducing metastasis risk in various cancers, potentially available as an extract or dietary supplement.
A Texas A&M AgriLife Research study found that peach extract inhibits breast cancer metastasis in mice by targeting metalloproteinases. Consuming two to three peaches per day may provide similar benefits for humans, according to the study published in the Journal of Nutritional Biochemistry.
Researchers have developed a new technology that uses 'nano-flares' to detect metastatic breast cancer cells in blood samples, which could lead to earlier diagnosis and improved treatment options. The technology has shown promising results in animal tests and is currently being experimented with human samples.
A genetic variant in SCN10A modifies cardiac expression of SCN5A, essential for conduction. An inflammatory feedback loop activates STAT3, repressing miR-34a and promoting EMT in colorectal cancer cells. Insulin resistance in bone disrupts glucose homeostasis through decreased active osteocalcin.
A 3,000 year-old skeleton has revealed evidence of metastatic carcinoma, making it the oldest convincing complete example of cancer in the archaeological record. Analysis suggests that environmental carcinogens or infectious diseases may have caused the cancer.
A recent study reveals that a key protein called IRSp53 plays a crucial role in regulating cell movement, which is necessary for wound healing and immune response. However, when cancer cells break away from tumors and migrate to other tissues, this regulation can be disrupted, leading to metastasis.
Researchers developed a novel therapy combining cryoablation with nanodrug chemotherapy to eliminate cancer stem-like cells. The treatment showed significant promise in eradicating CSCs, reducing the risk of cancer recurrence and metastasis. This innovative approach has great potential for improving cancer treatment outcomes.
Researchers at Johns Hopkins University have discovered that cancer cells do not follow a 'drunken' walk through the body, but rather move in more direct lines. This new understanding could lead to more accurate results for scientists studying how cancer spreads and may lead to more effective treatments.
Researchers at The Wistar Institute have discovered LIMD2, a protein that drives metastasis in various cancers. The study defines the structure of LIMD2 and its correlation with metastatic tumors, offering potential targets for treatment.
Researchers have successfully activated an immune system response in mice by applying localized heat to tumors, which then targeted and eliminated other tumor sites. This innovative approach uses iron-oxide nanoparticles and magnetic energy to kickstart the immune system against metastatic tumors.
Research published in the Journal of Clinical Investigation reveals that DLC1 suppresses breast cancer bone metastasis by inhibiting PTHLH production and regulating TGF-\u00b1 signaling. Clinical samples also show a correlation between reduced DLC1, elevated PTHLH, and bone metastasis.
Researchers discovered that cancer cells hug capillaries and express specific proteins to survive in the brain. The tumor cells produce a protein acting like Velcro to attach themselves to blood vessels, allowing them to grow into new tumors.
Researchers discovered that sunburns contribute to melanoma development through inflammatory processes in surrounding tissue. Melanoma cells migrate along blood vessels in inflamed skin, with activated neutrophils playing a key role in metastasis.
The National Cancer Institute (NCI) has rated The Wistar Institute Cancer Center as 'exceptional' and recommended a $14.9 million support grant renewal over five years. This rating highlights the center's commitment to scientific collaboration, research excellence, and translating discoveries into better cancer treatments.
A study of 285 stage III-IV SCCOP patients found that HPV-positive patients developed distant metastases later, in more subsites, and atypical sites compared to HPV-negative patients. The most common sites were lung and bone for both groups.
MIT researchers create a microfluidic platform that mimics the spread of breast cancer cells into a bonelike environment. The study found that certain molecules, such as CXCL5 and CXCR2, may encourage cancer cell metastasis, potentially leading to new targets for cancer therapy.
Researchers found that dormant prostate cancer cells can be reactivated by factors produced in inflammatory cells, such as RANKL. This discovery may allow for the development of new interventions to prevent disease progression and prolong survival.
Dormant prostate cancer cells in bone tissue can be reactivated to form secondary tumors when exposed to the signaling molecule RANKL. Researchers have discovered that this reactivation process may lead to metastatic prostate cancer in bones, and targeting it could prevent metastasis and improve survival rates.
A study of 52 patients with metastatic brain tumors found that early tumor shrinkage after stereotactic radiosurgery indicates a positive outcome, reducing the need for further monitoring. Tumors that did not respond initially were more likely to recur or require additional treatment.
Researchers at Cardiff University have identified a compound that potently inhibits Bcl3 and completely halts the spread of metastatic tumors in mice. The development aims to create a therapeutic agent capable of blocking metastatic disease in breast cancer and various tumor types.
Researchers have developed a new mouse model for metastatic prostate cancer, called RapidCaP, which reveals a specific role for Myc as a driver of metastasis in prostate cancer. The study suggests that targeting the Myc gene may provide a new approach to cure incurable prostate cancer.